STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

盘前交易 09-21 07:32:14 EDT

35.00

-0.10

-0.28%

盘前35.15

+0.15+0.43%

07:00 EDT

最高35.63	最低34.42	成交量154.80万
今开35.04	昨收35.10	日振幅3.47%
总市值24.96亿	流通市值19.12亿	总股本7,131万
成交额5,390万	换手率2.83%	流通股本5,464万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":35,"timestamp":1789761600000,"preClose":35.1,"halted":0,"volume":1548032,"hourTrading":{"tag":"盘前","latestPrice":35.15,"preClose":35,"latestTime":"07:00 EDT","volume":194,"amount":6843.41014,"timestamp":1789988412894,"change":0.15,"changeRate":0.004286,"amplitude":0.001429},"delay":0,"changeRate":-0.0028490028490028895,"floatShares":54641899,"shares":71309857,"eps":-3.1128,"marketStatus":"盘前交易","change":-0.1,"latestTime":"09-21 07:32:14 EDT","open":35.04,"high":35.6313,"low":34.415,"amount":53899898.314752005,"amplitude":0.034652,"askPrice":38.55,"askSize":100,"bidPrice":35.11,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-3.1128,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789997400000},"marketStatusCode":1,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":35,"preHourTrading":{"tag":"盘前","latestPrice":35.15,"preClose":35,"latestTime":"07:00 EDT","volume":194,"amount":6843.41014,"timestamp":1789988412894,"change":0.15,"changeRate":0.004286,"amplitude":0.001429},"postHourTrading":{"tag":"盘后","latestPrice":35,"preClose":35,"latestTime":"19:47 EDT","volume":56342,"amount":1972419.883,"timestamp":1789775223249,"change":0,"changeRate":0,"amplitude":0.005429},"volumeRatio":1.0941657153284865,"impliedVol":0.7358,"impliedVolPercentile":0.328},"requestUrl":"/m/hq/s/GPCR/wiki","defaultTab":"wiki","newsList":[{"id":"1165843596","title":"Structure Therapeutics旗下Aleniglipron在Access Ole试验中展现72周最高16.2%体重降幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1165843596","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165843596?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:03","pubTimestamp":1788868999,"startTime":"0","endTime":"0","summary":"Structure Therapeutics宣布，其候选药物Aleniglipron在Access Ole临床试验中取得了令人瞩目的成果——患者在72周的治疗周期内，体重减轻幅度最高达到16.2%。这一数据标志着该药物在长期减肥疗效方面迈出了坚实一步。此次公布的临床试验结果无疑为Structure Therapeutics注入了强劲动力。在长达72周的观察窗口内，Aleniglipron不仅展现出持续且显著的减重效果，更凸显了其在肥胖症治疗领域的巨大潜力。值得注意的是，这一长期数据进一步巩固了Aleniglipron的安全性及耐受性轮廓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129991235","title":"Structure Therapeutics候选药物Accg-2671展现约6天半衰期，未出现严重不良事件，1/2a期SAD试验中实现3.3%体重下降","url":"https://stock-news.laohu8.com/highlight/detail?id=1129991235","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129991235?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:03","pubTimestamp":1788868989,"startTime":"0","endTime":"0","summary":"Structure Therapeutics披露了其研发管线中备受关注的候选药物Accg-2671的最新临床数据。\n该公司表示，该药物在1/2a期单次递增剂量（SAD）临床试验中，展现出大约6天的半衰期特征。\n在安全性方面，研究过程中未观察到任何严重不良事件，表现令人鼓舞。\n此外，试验数据显示，受试者体重出现3.3%的下降幅度。这一系列积极结果或将为该药物后续的临床开发奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164454119","title":"Structure Therapeutics宣布ACCG-2671在12周MAD 1/2a期试验完成首批受试者给药，顶线数据预计2027年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1164454119","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164454119?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:02","pubTimestamp":1788868934,"startTime":"0","endTime":"0","summary":"Structure Therapeutics日前披露，其候选药物ACCG-2671在为期12周的多剂量递增1/2a期临床试验中，已完成首批受试者给药。据悉，这项研究旨在评估ACCG-2671的安全性、耐受性及药代动力学特征，为后续更为深入的疗效验证奠定基础。公司方面表示，该试验的顶线数据预计将于2027年上半年对外公布。市场分析人士认为，ACCG-2671若能按期交出令人满意的数据，或将进一步巩固Structure Therapeutics在代谢及心血管疾病治疗领域的前沿地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173437492","title":"Structure Therapeutics公布口服小分子Amylin与GLP-1项目在慢性体重管理中的积极临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1173437492","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173437492?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:01","pubTimestamp":1788868877,"startTime":"0","endTime":"0","summary":"Structure Therapeutics对外披露，其在口服小分子Amylin及GLP-1项目中，收获了针对慢性体重管理的积极临床数据。此番成果，无疑为该公司在代谢性疾病治疗领域的布局注入了强劲动力。这些发现，不仅彰显了其研发管线的潜力，也或将为未来肥胖症治疗开辟新的路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164246465","title":"新闻稿：Septerna任命资深行业专家Rajiv Patni医学博士担任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=1164246465","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164246465?lang=zh_cn&edition=full","pubTime":"2026-08-25 20:05","pubTimestamp":1787659519,"startTime":"0","endTime":"0","summary":"南旧金山，2026年8月25日——Septerna, Inc.，一家致力于开创G蛋白偶联受体药物发现新纪元的临床阶段生物技术公司，今日宣布任命Rajiv Patni医学博士为首席医疗官。Patni博士是一位兼具医师与科学家身份的生物制药高管，拥有超过25年领导研发、监管及医学事务组织的丰富经验。“在我的职业生涯中，我多次在研发轨迹的转折点加入公司，而Septerna正处在这一阶段，”Patni博士表示。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","GPCR","BK4599","BK4007","R","BK4232","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180747442","title":"Structure Therapeutics宣布，Aleniglipron在2B期试验中显示出长达36周以上最高达16.2%的减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1180747442","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180747442?lang=zh_cn&edition=full","pubTime":"2026-06-06 04:18","pubTimestamp":1780690711,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc.  近日公布了其口服GLP-1受体激动剂Aleniglipron在2B期临床试验中的积极顶线结果。数据显示，在为期36周的治疗期内，接受Aleniglipron治疗的患者实现了显著的体重减轻，最高减重幅度达到16.2%。这项随机、双盲、安慰剂对照的试验评估了不同剂量Aleniglipron在肥胖或超重成人中的疗效与安全性。除了显著的减重数据，Aleniglipron在改善血糖控制等次要终点上也表现出积极趋势。这一积极数据进一步验证了Aleniglipron作为潜在重磅口服减肥疗法的前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178081119","title":"Structure Therapeutics旗下阿伦利普隆展现良好耐受性，停药率仅为10.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178081119","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178081119?lang=zh_cn&edition=full","pubTime":"2026-06-06 04:18","pubTimestamp":1780690707,"startTime":"0","endTime":"0","summary":"Structure Therapeutics公司宣布，其研发的药物阿伦利普隆在临床试验中表现出良好的耐受性特征，患者停药率低至10.4%。这一数据突显了该药物在治疗过程中的可接受性与安全性，为其进一步的临床开发与应用奠定了积极基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154055283","title":"Structure Therapeutics修订并重述与Leerink Partners及Cantor Fitzgerald的销售协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1154055283","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154055283?lang=zh_cn&edition=full","pubTime":"2026-05-08 05:17","pubTimestamp":1778188666,"startTime":"0","endTime":"0","summary":"生物制药公司Structure Therapeutics Inc于2026年5月7日向美国证券交易委员会提交文件，宣布与Leerink Partners LLC及Cantor Fitzgerald & Co.共同签署经修订与重述的股权分销协议。该协议旨在优化公司未来通过\"at-the-market\"股权发行计划进行融资的运作框架。此次协议修订涉及分销条款、佣金结构及结算流程等核心商业条款的更新，标志着Structure Therapeutics与两家顶尖医疗健康领域投行深化战略合作的里程碑。通过完善销售协议机制，公司将进一步增强资本运作灵活性，为管线药物研发提供可持续的资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160867102","title":"Structure Therapeutics将ATM增发规模扩大1.5亿美元 总额达4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160867102","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160867102?lang=zh_cn&edition=full","pubTime":"2026-05-08 05:17","pubTimestamp":1778188634,"startTime":"0","endTime":"0","summary":"生物医药公司Structure Therapeutics Inc（股票代码：GPCR）近日向美国证券交易委员会提交文件，宣布将其ATM（按市价发行）股票增发计划规模扩大1.5亿美元。此次调整后，该公司的ATM增发总规模将达到4亿美元。\nATM增发机制允许上市公司在特定时期内，根据市场情况灵活地向公众发售新股。此次规模扩充将为Structure Therapeutics提供更充足的资金流动性，支持其临床阶段药物研发管线的推进。该公司专注于开发针对代谢性疾病的口服小分子疗法，此次融资安排彰显了其持续优化资本结构的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630391708","title":"埃诺格鲁肽注射液全国首批处方落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2630391708","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630391708?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:50","pubTimestamp":1777294212,"startTime":"0","endTime":"0","summary":"4月27日，新一代cAMP偏向型GLP-1受体激动剂埃诺格鲁肽注射液（先维盈）在北京大学人民医院与复旦大学附属中山医院同步开出全国首批处方，标志着这款创新体重管理疗法正式在中国迈入临床应用阶段。据悉，GLP-1受体激动剂的创新研发有两条路线。传统路线是以GLP-1为核心靶点叠加其他作用靶点，如GIP、GCG等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720616957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720616957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115849765","title":"Structure Therapeutics任命Matthew Lang为首席运营官兼总法律顾问","url":"https://stock-news.laohu8.com/highlight/detail?id=1115849765","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115849765?lang=zh_cn&edition=full","pubTime":"2026-04-15 04:07","pubTimestamp":1776197275,"startTime":"0","endTime":"0","summary":"旧金山，2026年4月14日——临床阶段全球生物制药公司Structure Therapeutics Inc.今日宣布，任命Matthew Lang, J.D. 为公司首席运营官兼总法律顾问。Lang先生在加入Structure Therapeutics时，已在全球生物制药机构拥有超过十五年的高管领导经验，其深厚专长涵盖法律、企业战略、合规、风险管理和业务发展等多个领域。Structure Therapeutics首席执行官Raymond Stevens博士表示：\"Matt是一位经验丰富的领导者，在引导组织实现增长和转型方面拥有卓越的业绩记录。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4232","LENZ","BK4007","GPCR","R","BK4599","BK4139","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518865271","title":"硕迪生物盘中异动 早盘股价大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518865271","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518865271?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:28","pubTimestamp":1741616909,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时28分，硕迪生物股票出现波动，股价大幅跳水5.11%。截至发稿，该股报21.47美元/股，成交量6.4194万股，换手率0.11%，振幅3.80%。机构评级方面，在所有13家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体涨幅为0.40%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222829a26a3aa9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222829a26a3aa9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148740425","title":"异动解读 | 硕迪生物GPCR股价盘中暴跌6.54%,因公司未有利好消息传出","url":"https://stock-news.laohu8.com/highlight/detail?id=1148740425","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148740425?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:28","pubTimestamp":1741102110,"startTime":"0","endTime":"0","summary":"硕迪生物(GPCR.US)股价今日盘中大跌6.54%,引发市场关注。\n\n从公开消息来看,硕迪生物是一家临床阶段的生物制药公司,主要产品为治疗糖尿病和肥胖症的口服候选药物GSBR-1290。但就目前来看,该公司并未传出任何重大利好消息,导致投资者对公司前景缺乏信心,加之部分资金选择了获利了结,因此可能是造成股价大跌的主要原因。\n\n不过值得注意的是,该股近期财务数据良好,去年全年虽然净亏损达1.23亿美元,但营收有望在新药上市后显著改善。另外机构给予的评级均为买入,显示出对公司长期前景的乐观预期。因此,只要公司研发顺利,未来随着新药问世,股价或将迎来反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 硕迪生物GPCR股价盘中暴跌6.54%,因公司未有利好消息传出","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516714608","title":"硕迪生物盘中异动 早盘股价大跌5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516714608","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516714608?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:19","pubTimestamp":1741101575,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时19分，硕迪生物股票出现波动，股价快速下挫5.42%。截至发稿，该股报21.13美元/股，成交量10.8238万股，换手率0.19%，振幅4.89%。机构评级方面，在所有12家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体涨幅为0.43%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231935a25f1345&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231935a25f1345&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634444","title":"硕迪生物盘中异动 急速跳水5.01%报22.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634444","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516634444?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:42","pubTimestamp":1741012932,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时42分，硕迪生物股票出现波动，股价大幅下挫5.01%。截至发稿，该股报22.56美元/股，成交量5.9494万股，换手率0.10%，振幅4.53%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-1.23亿美元，每股收益-2.33美元，毛利-2.60百万美元，市盈率-9.65倍。机构评级方面，在所有12家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体涨幅为0.19%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224212abe636c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224212abe636c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514202073","title":"硕迪生物盘中异动 早盘大幅下挫5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514202073","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514202073?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:41","pubTimestamp":1740753666,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时41分，硕迪生物股票出现异动，股价快速下挫5.30%。截至发稿，该股报21.61美元/股，成交量6.7562万股，换手率0.12%，振幅8.63%。机构评级方面，在所有12家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体涨幅为0.33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228224107a25803e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228224107a25803e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514635433","title":"Structure Therapeutics(GPCR.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.22美元，前值为-0.16美元，预期值为-0.17美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514635433","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514635433?lang=zh_cn&edition=full","pubTime":"2025-02-28 07:08","pubTimestamp":1740697726,"startTime":"0","endTime":"0","summary":"Structure Therapeutics(GPCR.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.22美元，前值为-0.16美元，预期值为-0.17美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28070848442551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["GPCR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169239315","title":"Structure Therapeutics 2024财年GAAP每股收益$(0.78)优于$(0.80)的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1169239315","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169239315?lang=zh_cn&edition=full","pubTime":"2025-02-28 06:14","pubTimestamp":1740694468,"startTime":"0","endTime":"0","summary":"Structure Therapeutics报告季度每股亏损$，优于分析师预期的$，提高了2.5％。与去年同期每股亏损$相比，这是一个3.7％的增长。以上内容来自Benzinga Earnings专栏，原文如下：Structure $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 2.5 percent. This is a 3.7 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514158339","title":"硕迪生物盘中异动 急速上涨5.28%报20.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514158339","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514158339?lang=zh_cn&edition=full","pubTime":"2025-02-28 02:59","pubTimestamp":1740682791,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日02时59分，硕迪生物股票出现异动，股价快速拉升5.28%。截至发稿，该股报20.93美元/股，成交量51.5012万股，换手率0.90%，振幅5.81%。机构评级方面，在所有11家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体涨幅为0.21%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228025952a256b6e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228025952a256b6e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514861634","title":"硕迪生物盘中异动 大幅下跌5.14%报20.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514861634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514861634?lang=zh_cn&edition=full","pubTime":"2025-02-27 03:10","pubTimestamp":1740597043,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日03时10分，硕迪生物股票出现波动，股价大幅跳水5.14%。截至发稿，该股报20.01美元/股，成交量29.5875万股，换手率0.52%，振幅6.99%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-34.26百万美元，每股收益-0.60美元，毛利-267175.50美元，市盈率-9.26倍。机构评级方面，在所有11家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体跌幅为0.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227031044abde29f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227031044abde29f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.structuretx.com","stockEarnings":[{"period":"1week","weight":-0.0947},{"period":"1month","weight":-0.3534},{"period":"3month","weight":-0.2137},{"period":"6month","weight":-0.2797},{"period":"1year","weight":0.5067},{"period":"ytd","weight":-0.4968}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.117}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"硕迪生物公司于2019年2月在开曼群岛成立，在美国和中国设有运营子公司。该公司是一家临床阶段的全球生物制药公司，旨在开发和提供新型口服疗法，以治疗各种慢性疾病，满足医疗需求。公司的差异化技术平台利用基于结构的药物发现和计算化学专业知识，使公司能够开发口服小分子疗法，用于治疗各种疾病，包括影响代谢、心血管和肺系统的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.149001},{"month":2,"riseRate":0,"avgChangeRate":-0.188474},{"month":3,"riseRate":0.25,"avgChangeRate":-0.12966},{"month":4,"riseRate":0.5,"avgChangeRate":0.102223},{"month":5,"riseRate":0.25,"avgChangeRate":-0.029871},{"month":6,"riseRate":0.75,"avgChangeRate":0.191173},{"month":7,"riseRate":0,"avgChangeRate":-0.102138},{"month":8,"riseRate":0.5,"avgChangeRate":-0.043717},{"month":9,"riseRate":0.75,"avgChangeRate":0.288194},{"month":10,"riseRate":0.666667,"avgChangeRate":0.200398},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.123384},{"month":12,"riseRate":0.333333,"avgChangeRate":0.164068}],"exchange":"NASDAQ","name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","nameEN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD,GPCR,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎国际,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股价,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股市,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票价格,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票交易,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票购买,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}